DelveInsight's "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), historical and forecasted epidemiology as well as the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market report provides current treatment practices, emerging drugs, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market share of the individual therapies, current and forecasted Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Patients with BPDCN have diverse clinical features, with cutaneous tumors in nearly all cases; the high incidence of such tumors distinguishes this disease from other myeloid cancers. Other sites of involvement include bone marrow, peripheral blood, lymph nodes, spleen, and other extramedullary organs. BPDCN can also evolve from prior myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML), so patients with such diseases and skin lesions should be evaluated for BPDCN specifically.
BPDCN can be referred by different names such as blastic NK cell lymphoma, agranular CD4+ NK cell leukemia, blastic NK leukemia/lymphoma, and agranular CD4+ CD56+ hematodermic neoplasm. Also, as per WHO 2016 classification, BPDCN is currently classified as a distinct entity within the myeloid neoplasm and acute leukemia classification.
It covers the details of conventional and current medical therapies and diagnosis available in the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithm across the United States, Europe, and Japan.
The DelveInsight Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market report gives a thorough understanding of BPDCN symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides BPDCN symptoms of treatment algorithms and treatment guidelines for BPDCN symptoms in the US, Europe, and Japan.
The diagnosis of BPDCN has evolved as clinical and pathological technologies have improved and enhanced. A series of molecular studies based on karyotyping, gene expression profiling, and next generation sequencing, have largely unveiled the pathobiology of the tumour and proposed the potentially beneficial use of new drugs. Intensified chemotherapy with or without stem cell transplantation showed an objective response. The differential diagnoses include myeloid sarcoma/acute myeloid leukemia, T-cell lymphoblastic leukemia/lymphoma, NK-cell lymphoma/leukemia, and some mature T-cell lymphomas/leukemias. Along with this, with the improved identification of mutation and biomarkers, recently, targeted therapies have come into the attention.
The FDA has approved Stemline Therapeutics’ tagraxofusp-erzs (Elzonris), targeting CD123 as the first drug approved to treat BPDCN.
The Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) epidemiology division provide insights about historical and current Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
Country Wise- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology
The epidemiology segment also provides the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total incident population of BPDCN in 7MM countries was estimated to be 1,786 cases in 2017.
Drug chapter segment of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) report encloses the detailed analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Emerging Drugs
MB-102: Mustang Bio
MB-102 (CD123 CAR T) is a CAR T cell therapy that is produced by engineering patient T cells to recognize and eliminate CD123-expressing tumors. CD123 is widely expressed on bone marrow cells of patients with myelodysplastic syndromes, as well as in hematologic malignancies, including AML, B-cell acute lymphoblastic leukemia, hairy cell leukemia, BPDCN chronic myeloid leukemia and Hodgkin’s lymphoma. Currently Mustang Bio is conducting Phase I/II clinical studies for BPDCN, AML and MDS. The FDA granted Orphan Drug Designation to MB-102 (CD123 CAR T) 2018 for the treatment of blastic plasmacytoid dendritic cell neoplasm.
Products detail in the report…
The Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market in 7MM is expected to grow in the study period 2017–2030.
There is no established standard therapy for BPDCN, and the efficacy of conventional chemotherapy is limited, with an anticipated median overall survival less than a year, if left untreated. Due to the lack of prospective clinical trials, there had been no universally accepted standard of care.
Tagraxofusp is a CD123 directed recombinant fusion protein, which leads to translocation of the diphtheria toxin fragment to the cytosol, followed by ADP ribosylation of elongation factor 2, with the resultant cessation of protein synthesis and cell death.
Patients with BPDCN may also be treated with regimens derived from the management of more common hematological malignancies, including non-Hodgkin lymphoma (cyclophosphamide/hydroxydaunomycin/vincristine/prednisone [CHOP] or [CHOP-like], acute lymphoblastic leukemia [ALL]; hyperfractionated/cyclophosphamide/vincristine/ doxorubicin/dexamethasone [hyper-CVAD] alternating with methotrexate and cytarabine), and AML. Autologous (auto) or allo-HCT (Hematopoietic cell transplantation) has been utilized as consolidative therapy in patients with BPDCN.
Key Findings
This section includes a glimpse of the Blastic plasmacytoid dendritic cell neoplasm (BPDCN) market in 7MM. The market size of BPDCN in the seven major markets was found to be USD 17.79 million in 2017.
The United States Market Outlook
This section provides the total Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market size and market size by therapies in the United States.
EU-5 Countries: Market Outlook
The total Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Market Outlook
The total Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market size and market size by therapies in Japan is also mentioned.
This section focusses on the rate of uptake of the potential drugs recently launched in the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase I, and Phase II stage. It also analyses Blastic plasmacytoid dendritic cell neoplasm (BPDCN) key players involved in developing targeted therapeutics.
Major players include AbbVie, Mustang Bio, Xencor, Inc and others.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Blastic plasmacytoid dendritic cell neoplasm (BPDCN) emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
"
1. Key Insights
2. Executive summary
3. Organizations
4. Epidemiology and Market Methodology
5. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Market Overview at a Glance
5.1. Total Market Share (%) Distribution of BPDCN in 2017
5.2. Total Market Share (%) Distribution of BPDCN in 2030
6. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Disease Overview
6.1. Introduction
6.2. Classification
6.3. Clinical Presentation
6.4. Pathogenesis
6.5. Diagnosis
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Total cases of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 7MM
7.3. United States
7.3.1. Assumptions and Rationale
7.3.2. Total Incident cases of Blastic plasmacytoid dendritic cell neoplasm in the United States
7.3.3. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in the United States
7.3.4. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm in the United States
7.4. EU5 Countries
7.5. Assumptions and Rationale
7.6. Germany
7.6.1. Assumptions and Rationale
7.6.2. Total Incident cases of BPDCN in Germany
7.6.3. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in Germany
7.6.4. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm in Germany
7.7. France
7.7.1. Assumptions and Rationale
7.7.2. Total Incident cases of BPDCN in France
7.7.3. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in France
7.7.4. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm France
7.8. Italy
7.8.1. Total Incident cases of BPDCN in Italy
7.8.2. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in Italy
7.8.3. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm in Italy
7.9. Spain
7.9.1. Total Incident cases of BPDCN in Spain
7.9.2. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in Spain
7.9.3. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm Spain
7.10. UK
7.10.1. Total Incident cases of BPDCN in the United Kingdom
7.10.2. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in the United Kingdom
7.10.3. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasmin the United Kingdom
7.11. Japan
7.11.1. Assumptions and Rationale
7.11.2. Total Incident cases of BPDCN in Japan
7.11.3. Gender-Specific cases of Blastic plasmacytoid dendritic cell neoplasm in Japan
7.11.4. Age-specific cases of Blastic plasmacytoid dendritic cell neoplasm in Japan
8. Current Treatment Practices
8.1. Treatment Algorithm
9. Unmet Needs
10. Marketed drugs
11. Elzonris: Stemline Therapeutics
11.1. Drug Description
11.2. Regulatory Milestones
11.3. Other Development Activities
11.4. Clinical Development
11.5. Safety and Efficacy
11.6. Product Profile
12. Emerging Therapies
13. Key Cross Competition
14. MB-102: Mustang Bio
14.1. Product Description
14.2. Other Developmental Activities
14.3. Clinical Development
14.4. Safety and Efficacy
14.5. Product Profile
15. IMGN632: ImmunoGen/ Jazz Pharmaceuticals
15.1. Drug Description
15.2. Clinical Development
15.3. Safety and Efficacy
15.4. Product Profile
16. UniCAR02-T-CD123: Cellex Patient Treatment GmbH
16.1. Drug Description
16.2. Other Developmental Activities
16.3. Clinical Development
16.4. Product Profile
17. Venetoclax: AbbVie
17.1. Drug Description
17.2. Other Developmental Activities
17.3. Clinical Development
17.4. Safety and Efficacy
17.5. Product Profile
18. XmAb14045: Xencor
18.1. Drug Description
18.2. Other Developmental Activities
18.3. Clinical Development
18.4. Safety and Efficacy
18.5. Product Profile
19. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): 7 Major Market Analysis
19.1. Key Findings
19.2. Market Size of Blastic plasmacytoid dendritic cell neoplasm in 7MM
20. Seven Major Market Outlook
20.1. United States Market Size
20.1.1. Total Market Size of Blastic plasmacytoid dendritic cell neoplasm in the United States
20.1.2. Total Market Size of Blastic plasmacytoid dendritic cell neoplasm by Line of Therapies in the United States
20.2. Germany
20.2.1. Total market size of Blastic plasmacytoid dendritic cell neoplasm in Germany
20.2.2. Total market size of Blastic plasmacytoid dendritic cell neoplasm by Line of Therapies in Germany
20.3. France
20.3.1. Total market size of Blastic plasmacytoid dendritic cell neoplasm in France
20.3.2. Total Market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in France
20.4. Italy
20.4.1. Total market size of Blastic plasmacytoid dendritic cell neoplasm in Italy
20.4.2. Total Market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in Italy
20.5. Spain
20.5.1. Total Market Size of Blastic plasmacytoid dendritic cell neoplasm in Spain
20.5.2. Total market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in Spain
20.6. United Kingdom
20.6.1. Total market size of Blastic plasmacytoid dendritic cell neoplasm in the United Kingdom
20.6.2. Total market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in the UK
20.7. Japan
21. Total market size of Blastic plasmacytoid dendritic cell neoplasm in Japan
22. Total market size of Blastic plasmacytoid dendritic cell neoplasm by by Line of Therapies in Japan
23. Market Drivers
24. Market Barriers
25. SWOT Analysis
26. Reimbursement policies
26.1. Current Therapies
27. Case Study
27.1. A Case Report of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
27.2. A Challenging Blastic Plasmacytoid Dendritic Cell Neoplasm Case
28. KOL Views
29. Appendix
30. Report Methodology
31. DelveInsight Capabilities
32. Disclaimer
33. About DelveInsight
34. Bibliography
Table 1 : 7MM Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology (2017-2030)
Table 2 : 7MM Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases (2017-2030)
Table 3 : Disease% Epidemiology in the United States (2017-2030)
Table 4 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in the United States (2017-2030)
Table 5 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in Germany (2017-2030)
Table 6 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in Germany (2017-2030)
Table 7 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in France (2017-2030)
Table 8 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in France (2017-2030)
Table 9 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in Italy (2017-2030)
Table 10 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in Italy (2017-2030)
Table 11 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in Spain (2017-2030)
Table 12 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in Spain (2017-2030)
Table 13 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in the UK (2017-2030)
Table 14 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in the UK (2017-2030)
Table 15 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in Japan (2017-2030)
Table 16 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in Japan (2017-2030)
Table 17 : Drug Name, Clinical Trials by Recruitment status
Table 18 : Drug Name, Clinical Trials by Zone
Table 19 : Total Seven Major Market Size in USD, Million (2017-2030)
Table 20 : Region-wise Market Size in USD, Million (2017-2030)
Table 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
Table 22 : United States Market Size in USD, Million (2017-2030)
Table 23 : United States Market Size by Therapy in USD, Million (2017-2030)
Table 24 : Germany Market Size in USD, Million (2017-2030)
Table 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
Table 26 : France Market Size in USD, Million (2017-2030)
Table 27 : France Market Size by Therapy in USD, Million (2017-2030)
Table 28 : Italy Market Size in USD, Million (2017-2030)
Table 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
Table 30 : Spain Market Size in USD, Million (2017-2030)
Table 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
Table 32 : United Kingdom Market Size in USD, Million (2017-2030)
Table 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
Table 34 : Japan Market Size in USD, Million (2017-2030)
Table 35 : Japan Market Size by Therapy in USD, Million (2017-2030)
*The list of tables is not exhaustive; the final content may vary
Figure 1 : 7MM Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology (2017-2030)
Figure 2 : 7MM Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases (2017-2030)
Figure 3 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in the United States (2017-2030)
Figure 4 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in the United States (2017-2030)
Figure 5 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in Germany (2017-2030)
Figure 6 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in Germany (2017-2030)
Figure 7 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in France (2017-2030)
Figure 8 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in France (2017-2030)
Figure 9 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in Italy (2017-2030)
Figure 10 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in Italy (2017-2030)
Figure 11 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in Spain (2017-2030)
Figure 12 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in Spain (2017-2030)
Figure 13 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in the UK (2017-2030)
Figure 14 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in the UK (2017-2030)
Figure 15 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Epidemiology in Japan (2017-2030)
Figure 16 : Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Diagnosed and Treatable Cases in Japan (2017-2030)
Figure 17 : Drug Name, Clinical Trials by Recruitment status
Figure 18 : Drug Name, Clinical Trials by Zone
Figure 19 : Total Seven Major Market Size in USD, Million (2017-2030)
Figure 20 : Region-wise Market Size in USD, Million (2017-2030)
Figure 21 : 7MM-Market Size by Therapy in USD, Million (2017-2030)
Figure 22 : United States Market Size in USD, Million (2017-2030)
Figure 23 : United States Market Size by Therapy in USD, Million (2017-2030)
Figure 24 : Germany Market Size in USD, Million (2017-2030)
Figure 25 : Germany Market Size by Therapy in USD, Million (2017-2030)
Figure 26 : France Market Size in USD, Million (2017-2030)
Figure 27 : France Market Size by Therapy in USD, Million (2017-2030)
Figure 28 : Italy Market Size in USD, Million (2017-2030)
Figure 29 : Italy Market Size by Therapy in USD, Million (2017-2030)
Figure 30 : Spain Market Size in USD, Million (2017-2030)
Figure 31 : Spain Market Size by Therapy in USD, Million (2017-2030)
Figure 32 : United Kingdom Market Size in USD, Million (2017-2030)
Figure 33 : United Kingdom Market Size by Therapy in USD, Million (2017-2030)
Figure 34 : Japan Market Size in USD, Million (2017-2030)
Figure 35 : Japan Market Size by Therapy in USD, Million (2017-2030)
*The list of figures is not exhaustive; the final content may vary.
Stemline Therapeutics
Mustang Bio
ImmunoGen/ Jazz Pharmaceuticals
Cellex Patient Treatment GmbH
AbbVie
Xencor
